The drug maker presented Phase I data for PF-08046040 at ASH, having designed it to avoid some of the toxicities associated with antibody-drug conjugates.
An increasingly popular antigen in hematology-oncology as well as solid tumor oncology is CD70, with a number of players developing therapies to target it. But Pfizer believes its PF-08046040, acquired through its purchase of Seagen, could target CD70 in a way more amenable to elderly patients.
The drug maker presented Phase I data in a poster on 7 December at the American Society of Hematology annual...
Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.
Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.
With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.
BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
